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Summary
Background Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic 
acid has shown potential anticancer eﬀ ects in preclinical and clinical studies. We aimed to establish whether 
bisphosphonates can aﬀ ect clinical outcomes in patients with multiple myeloma.
Methods Patients of age 18 years or older with newly diagnosed multiple myeloma were enrolled from 120 centres in 
the UK. Computer-generated randomisation sequence was used to allocate patients equally, via an automated 
telephone service, to receive 4 mg zoledronic acid as an infusion every 3–4 weeks or 1600 mg oral clodronic acid daily. 
Patients also received intensive or non-intensive induction chemotherapy. No investigators, staﬀ , or patients were 
masked to treatment allocation, and bisphosphonate and maintenance therapy continued at least until disease 
progression. The primary endpoints were overall survival, progression-free survival, and overall response rate. We 
assessed between-group diﬀ erences with Cox proportional hazards models for progression-free survival and overall 
survival, and with logistic regression models for overall response rate. Analysis was by intention to treat. This trial is 
registered, number ISRCTN68454111.
Findings 1970 patients were enrolled between May, 2003, and November, 2007, of whom 1960 were eligible for 
intention-to-treat analysis: 981 in the zoledronic acid group (555 on intensive chemotherapy, 426 on non-intensive 
chemotherapy); and 979 on clodronic acid (556 on intensive chemotherapy, 423 on non-intensive chemotherapy). The 
treatment cutoﬀ  was Oct 5, 2009, with patients receiving bisphosphonates for a median of 350 days (IQR 137–632) 
before disease progression, with a median of 3·7 years’ follow-up (IQR 2·9–4·7). Zoledronic acid reduced mortality 
by 16% (95% CI 4–26) versus clodronic acid (hazard ratio [HR] 0·84, 95% CI 0·74–0·96; p=0·0118), and extended 
median overall survival by 5·5 months (50·0 months, IQR 21·0 to not reached vs 44·5 months, IQR 16·5 to not 
reached; p=0·04). Zoledronic acid also signiﬁ cantly improved progression-free survival by 12% (95% CI 2–20) versus 
clodronic acid (HR 0·88, 95% CI 0·80–0·98; p=0·0179), and increased median progression-free survival by 2·0 months 
(19·5 months, IQR 9·0–38·0 vs 17·5 months, IQR 8·5–34·0; p=0·07). Rates of complete, very good partial, or partial 
response did not diﬀ er signiﬁ cantly between the zoledronic acid and clodronic acid groups for patients receiving 
intensive induction chemotherapy (432 patients [78%] vs 422 [76%]; p=0·43) or non-intensive induction chemotherapy 
(215 [50%] vs 195 [46%]; p=0·18). Both bisphosphonates were generally well tolerated, with similar occurrence of 
acute renal failure and treatment-emergent serious adverse events, but zoledronic acid was associated with higher 
rates of conﬁ rmed osteonecrosis of the jaw (35 [4%]) than was clodronic acid (3 [<1%]).
Interpretation Consistent with the potential anticancer activity of zoledronic acid, overall survival improved 
independently of prevention of skeletal-related events, showing that zoledronic acid has treatment beneﬁ ts beyond 
bone health. These ﬁ ndings support immediate treatment with zoledronic acid in patients with newly diagnosed 
multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyeloma beneﬁ ts.
Funding Medical Research Council (London, UK), with unrestricted educational grants from Novartis, Schering 
Health Care, Chugai, Pharmion, Celgene, and Ortho Biotech.
Introduction
Myeloma is a plasma-cell malignant disease that 
can result in osteolytic lesions, excess immuno-
globulin secretion, impaired renal function, and 
myelosuppression.1 Myeloma plasma cells live in the 
bone marrow microenvironment1,2 and can secrete 
factors that stimulate osteoclast-mediated osteolysis,2 
placing patients at risk for skeletal-related events 
such as fractures and bone pain requiring pallia tive 
radiotherapy.3
Bisphosphonates were developed mainly to impair 
malignant osteolysis, thereby breaking the cycle of bone 
destruction and cancer growth that can result in 
skeletal-related events.4 By blocking growth-factor 
release from the bone matrix, bisphosphonates can 
indirectly impede myeloma growth.5 Preclinical evidence 
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suggests that bisphosphonates—especially nitrogen-
containing bisphosphonates such as zoledronic acid—
might have inherent anticancer activities.4,6 Moreover, 
zoledronic acid signiﬁ cantly extended survival in two 
mouse models of multiple myeloma.7,8 The antimyeloma 
eﬀ ect was independent of the eﬀ ect of zoledronic acid 
on bone, but dependent on inhibition of protein 
prenylation,8 a mechanism of action not shared by 
non-nitrogen-containing bisphosphonates such as 
clodronic acid (clodronate).4
Although diﬀ erences in overall survival with 
bisphosphonates were not signiﬁ cant in the full 
populations of large randomised controlled trials in 
multiple myeloma,9–12 bisphosphonates seemed to 
improve overall survival in subsets of patients in phase 3 
studies.9–11 For example, in the UK Medical Research 
Council (MRC) trial in patients with bone lesions from 
multiple myeloma (n=535), overall survival was similar 
between clodronic acid and placebo in the full population, 
but clodronic acid signiﬁ cantly improved overall survival 
versus placebo in the subset of patients who had not had 
fractures before study entry (n=153; p=0·006).11 
Furthermore, in large-scale randomised trials in patients 
undergoing adjuvant endocrine therapy for early breast 
cancer, zoledronic acid signiﬁ cantly extended disease-
free survival (n=1803 and n=1065),13,14 and clodronic acid 
extended overall survival in patients with metastatic 
prostate cancer (n=278).15 Moreover, zoledronic acid 
showed anticancer synergy with some chemotherapy 
agents in preclinical assays.6 Therefore, bisphosphonates 
might aﬀ ect the disease course of multiple myeloma.
Despite strong consensus that antimyeloma therapies 
should be given to symptomatic patients with multiple 
myeloma,16,17 no optimal regimen has emerged. Therefore, 
we designed the MRC Myeloma IX trial, an innovative 
study with two randomisation steps to allow comparison 
of both ﬁ rst-line and maintenance treatments for adult 
patients with newly diagnosed multiple myeloma. The 
ﬁ rst randomisation step compared oral clodronic acid 
and an intravenous bisphosphonate with respect to 
overall survival, progression-free survival, response rates, 
and skeletal-related events. Of the two intravenous 
bisphosphonates approved for prevention of skeletal-
related events in multiple myeloma, pamidronic acid 
(pamidronate) and zoledronic acid, we selected zoledronic 
acid because it has higher antiresorbtive activity and 
shorter infusion time than does pamidronic acid.4,12
Methods
Patients
In the MRC Myeloma IX trial, adult patients of age 
18 years or older who had newly diagnosed and 
histologically conﬁ rmed symptomatic multiple myeloma 
were enrolled from 120 centres in the UK. Patients were 
excluded if they had previous or concurrent active 
malignancies, had acute renal failure (serum creatinine 
>500 μmol/L and unresponsive to 72 h of rehydration, 
urine output <400 mL/day, or need for dialysis), had 
previously received treatment for myeloma (apart 
from local radiotherapy, bisphosphonates, or low-dose 
corticosteroids), or were pregnant or lactating. A strict 
risk-management programme was adopted, and all 
patients who were women of childbearing potential, or 
were men engaging in heterosexual activity with a woman 
of childbearing potential, had to use contraception.
The trial was approved by the North West Multi-centre 
Research Ethics Committee, and by local review 
committees at all participating centres. All patients 
provided written informed consent.
Randomisation and masking
The Clinical Trials Research Unit of the University of 
Leeds, Leeds, UK, used a computer-generated ran-
domisation sequence to assign treatment groups via an 
automated telephone service. The trial had a two-by-two 
factorial design, with two randomisation steps and equal 
allocation to two groups at each randomisation step. The 
ﬁ rst randomisation step compared ﬁ rst-line treatments, 
and the second compared maintenance treatments. The 
ﬁ rst randomisation used a minimisa tion algorithm 
stratiﬁ ed by centre, haemoglobin (<115 vs ≥115 g/L for 
men, <95 vs ≥95 g/L for women), serum calcium 
(<2·6 vs ≥2·6 mmol/L; corrected for serum albumin), 
serum creatinine (<140 vs ≥140 μmol/L), and platelet 
count (<150×10⁹/L or ≥150×10⁹/L). The maintenance 
randomisation used a minimisation algorithm stratiﬁ ed 
by centre and treatment group allocated at ﬁ rst 
randomisation. In this open-label trial, no investigators, 
staﬀ  at participating centres, or patients were masked to 
treatment allocation apart from individuals analysing 
treatment response from laboratory results.
Procedures
Before randomisation, patients were allocated to receive 
induction chemotherapy via one of two pathways, 
intensive and non-intensive. Pathway selection had no 
rigid age cutoﬀ  and was based on performance status, 
clinician judgment, and patient preference. The intensive 
pathway consisted of four–six 21-day cycles of either 
CVAD (500 mg oral cyclophosphamide per week, 0·4 mg 
vincristine daily combined with 9 mg/m² doxorubicin 
Figure 1: Trial proﬁ le
*Patients were included in the safety population. †Two patients on zoledronic 
acid received a conditioning regimen other than high-dose melphalan and 
underwent subsequent autologous stem-cell transplantation. ‡One patient in 
the non-intensive pathway who was excluded because no consent was received 
was then included in the randomisation to receive maintenance treatment; some 
of the 23 patients in the intensive pathway who did not start CVAD or CTD did 
receive high-dose melphalan plus autologous stem-cell transplantation, but 
none was included in the randomisation to receive maintenance treatment; none 
of the 12 patients in the non-intensive pathway who did not start MP or CTDa 
was included in the randomisation to receive maintenance treatment. 
CVAD=cyclophosphamide, vincristine, doxorubicin, and dexamethasone. 
CTD=cyclophosphamide, thalidomide, and dexamethasone. MP=melphalan and 
prednisolone. CTDa=attenuated CTD. BD=bortezomib and dexamethasone.
For more on the MRC 
Myeloma IX trial see http://ctru.
leeds.ac.uk/myelomaIX
Articles
www.thelancet.com   Vol 376   December 11, 2010 1991
3 excluded
1 duplicate patient
1 no consent received
1 misdiagnosed
7 excluded
1 duplicate patient
2 no consent received*
4 misdiagnosed
1114 patients randomised to receive ﬁrst-line bisphosphonate treatment plus intensive 
induction chemotherapy
856 patients randomised to receive ﬁrst-line bisphosphonate treatment plus non-intensive 
induction chemotherapy
2 excluded
1 no consent received
1 withdrew consent
1111 eligible for intention-to-treat analysis
818 eligible for intention-to-treat analysis
408 assigned to receive thalidomide 410 assigned to receive no thalidomide
195 initially randomised to receive 
clodronic acid
190 did not start thalidomide
3 started thalidomide
2 data missing for treatment received
215 initially randomised to receive 
zoledronic acid
212 did not start thalidomide
1 started thalidomide
2 data missing for treatment received
195 initially randomised to receive
clodronic acid
184 started thalidomide
5 did not start thalidomide
3 other
2 missing reason
6 data missing for treatment received
193 started thalidomide
13 did not start thalidomide
1 died
12 other
7 data missing for treatment received
213 initially randomised to receive 
zoledronic acid
820 randomised to receive maintenance treatment‡
255 on zoledronic acid (intensive pathway)
238 on clodronic acid (intensive pathway)
175 on zoledronic acid (non-intensive pathway)
152 on clodronic acid (non-intensive pathway)
849 eligible for intention-to-treat analysis
548 started CTD
7 did not start CTD
6 other
1 missing reason
278 assigned to
receive clodronic
acid plus CVAD
211 assigned to
receive clodronic
acid plus MP
278 assigned to
receive zoledronic
acid plus CVAD
212 assigned to
receive zoledronic
acid plus MP
277 assigned to
receive zoledronic
acid plus CTD
214 assigned to
receive zoledronic
acid plus CTDa
278 assigned to
receive clodronic
acid plus CTD 
212 assigned to
receive clodronic
acid plus CTDa 
540 started CVAD
16 did not start CVAD
4 died before start of treatment
8 other
4 missing reason
418 started MP
5 did not start MP
2 died before start of treatment
3 other
419 started CTDa
7 did not start CTDa
2 died before start of treatment
3 other
2 missing reason
6 patients showing no
change or progressive
disease after two cycles
of CTD or CVAD received
a third course of CTD or
CVAD and then might
have  been eligible to
receive BD  (optional
non-responders
subprotocol) 
747 received 200 mg/m2 melphalan and 
autologous stem-cell transplantation
383 on zoledronic acid
364 on clodronic acid
364 did not receive high-dose melphalan
plus autologous stem-cell transplantation
129 patient not ﬁt or clinician’s decision
93 died
29 patient’s decision
15 inadequate number of stem cells
98 other†
618 excluded
406 not eligible
144 not willing
68 missing reason
Patients with potential 
sibling donors oﬀered a 
low-intensity allogeneic
procedure
Intensive pathway Non-intensive pathway
849 maximal response
523 excluded
433 not eligible
53 not willing
37 missing reason
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daily as a 4-day continuous infusion, and 40 mg 
dexamethasone daily on days 1–4 and 12–15), or oral CTD 
(500 mg cyclophosphamide per week, 100 mg thalidomide 
daily and increasing to 200 mg daily as tolerated, and 
40 mg dexamethasone daily on days 1–4 and 12–15). After 
completion of induction therapy, patients underwent 
peripheral blood stem-cell mobilisation and harvest, high-
dose melphalan treatment (200 mg/m²), and autologous 
stem-cell transplantation. The non-intensive pathway 
consisted of six–nine 28-day cycles of either oral MP 
(7 mg/m² melphalan and 40 mg prednisolone, both on 
days 1–4), or attenuated oral CTD (CTDa; 500 mg 
cyclophosphamide per week, 50 mg thalidomide daily 
initially and increasing to 200 mg daily as tolerated, and 
20 mg dexamethasone daily on days 1–4 and 15–18); 
treatment was continued until best response.
In the ﬁ rst randomisation, patients in the intensive 
pathway were allocated to receive either clodronic acid or 
zoledronic acid plus induction chemotherapy with either 
CVAD or CTD, and patients in the non-intensive pathway 
were allocated to receive either clodronic acid or zoledronic 
acid plus induction chemotherapy with either MP or 
CTDa. Clodronic acid was given at a dose of 1600 mg per 
day orally, and zoledronic acid at a dose of 4 mg as a 
15-min infusion every 3–4 weeks during induction 
chemotherapy and every 4 weeks thereafter. The dose of 
zoledronic acid was adjusted for patients with impaired 
renal function at baseline, and was delayed in patients 
with raised creatinine concentrations during the study, as 
per the prescribing information. After ﬁ rst-line therapy 
(about 100 days after autologous stem-cell transplantation 
in the intensive pathway), the second randomisation 
allocated eligible patients (no disease progression, and 
opted to continue study treatment according to the 
protocol) to receive either maintenance therapy with 
50 mg thalidomide daily and increasing to 100 mg daily if 
tolerated, or no further treatment. Bisphosphonates and 
main tenance therapy were given continuously at least 
until disease progression.
We followed the recommendations of Weitzman and 
colleagues18 to reduce the risk of osteonecrosis of the jaw 
and to identify and manage such cases.18 All suspected 
cases of osteonecrosis of the jaw were referred to a dental 
professional for diagnosis and management, and reports 
were centrally reviewed by an investigator.
The primary endpoints were overall survival, 
progression-free survival, and overall response rate. 
Secondary endpoints included skeletal-related events and 
toxic eﬀ ects. Overall survival and progression-free 
survival were calculated from ﬁ rst randomisation to 
death or to progression or death, respectively. Patients 
with missing follow-up data were censored at the last 
date they were known to be alive (overall survival), or 
alive without disease progression.
In both the intensive and non-intensive pathways, 
disease was assessed after each cycle of induction 
chemotherapy (before high-dose melphalan and 
autologous stem-cell transplantation in the intensive 
pathway), and every 3 months thereafter, with an 
assessment at 100 days after transplantation in the 
intensive pathway. Treatment response was monitored 
centrally at the University of Birmingham, Birmingham, 
UK, from serum and urine protein and free light-chain 
studies, or, if results of such studies were missing, by 
review of local laboratory results in which results were 
veriﬁ ed by an independent response-assessment panel. 
Assessors at the central laboratory were masked with 
respect to treatment; assessors of local laboratory results 
Intensive pathway Non-intensive pathway
Zoledronic acid 
(n=555)
Clodronic acid 
(n=556)
Zoledronic acid 
(n=426)
Clodronic acid 
(n=423)
Age (years; median [range, IQR]) 59 (31–74, 
53–63)
59 (33–78, 
53–63)
73 (59–89, 
70–77)
73 (57–88, 
70–77)
Sex
Female 201 (36%) 218 (39%) 191 (45%) 185 (44%)
Male 354 (64%) 338 (61%) 235 (55%) 238 (56%)
ISS disease stage
I 129 (23%) 146 (26%) 63 (15%) 47 (11%)
II 198 (36%) 182 (33%) 139 (33%) 173 (41%)
III 174 (31%) 169 (30%) 173 (41%) 160 (38%)
Data unavailable 54 (10%) 59 (11%) 51 (12%) 43 (10%)
β2-microglobulin (mg/L) 4 (3–7) 4 (3–7) 5 (3–8) 5 (4–8)
Data unavailable 43 (8%) 52 (9%) 47 (11%) 37 (9%)
Myeloma subtype
IgG 332 (60%) 328 (59%) 253 (59%) 252 (60%)
IgM 2 (<1%) 3 (1%) 1 (<1%) 2 (<1%)
IgA 125 (23%) 116 (21%) 99 (23%) 102 (24%)
IgD 12 (2%) 13 (2%) 9 (2%) 4 (1%)
Light chain or non-expressing 78 (14%) 89 (16%) 58 (14%) 57 (13%)
Data unavailable 6 (1%) 7 (1%) 6 (1%) 6 (1%)
Bone disease
Yes 404 (73%) 411 (74%) 291 (68%) 295 (70%)
No 149 (27%) 138 (25%) 130 (31%) 123 (29%)
Data unavailable 2 (<1%) 7 (1%) 5 (1%) 5 (1%)
Bone pain
Yes 428 (77%) 415 (75%) 275 (65%) 287 (68%)
No 120 (22%) 132 (24%) 147 (35%) 131 (31%)
Data unavailable 7 (1%) 9 (2%) 4 (1%) 5 (1%)
Calcium after hydration (mmol/L) 2·4 (2·2–2·5) 2·4 (2·3–2·5) 2·4 (2·2–2·5) 2·4 (2·3–2·5)
Data unavailable* 37 (7%) 51 (9%) 37 (9%) 37 (9%)
Creatinine after hydration 
(μmol/L)
100 (84–128) 96 (79–122) 101 (82–128) 105 (88–137)
Data unavailable* 38 (7%) 48 (9%) 32 (8%) 34 (8%)
Haemoglobin (g/L) 110 (90–120) 110 (90–120) 100 (90–120) 110 (100–120)
Data unavailable* 19 (3%) 20 (4%) 20 (5%) 15 (4%)
Platelets (×109/L) 237 (186–308) 246 (194–310) 226 (177–292) 230 (177–292)
Data unavailable* 19 (3%) 20 (4%) 20 (5%) 15 (4%)
Data are median (IQR) or number of patients (%), unless otherwise indicated. ISS=international staging system. *For all 
variables included in the minimisation algorithm, the stratiﬁ cation category (eg, serum calcium <2·6 vs ≥2·6 mmol/L) 
was recorded for all patients, even if the exact value was not documented.
Table 1: Demographic and disease characteristics at baseline (intention-to-treat population)
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had access to treatment allocation information, but such 
information was not taken into consideration in 
assessment of response. Responses and disease 
progression were deﬁ ned according to international 
response criteria.19 Brieﬂ y, complete response was deﬁ ned 
as negative immunoﬁ xation (100% M-protein reduction), 
and very good partial response was deﬁ ned as at least 
90% M-protein reduction with positive immunoﬁ xation.19 
Safety was assessed by continuous monitoring of adverse 
events. Serum creatinine was monitored monthly during 
induction chemotherapy and, thereafter, monthly for 
zoledronic acid and every 3 months for clodronic acid. 
Serious adverse events were deﬁ ned as treatment 
emergent if they were judged by the treating physician to 
be potentially related to study drugs. Data for skeletal-
related events, deﬁ ned as vertebral fractures, other 
fractures, spinal cord compression, need for radiation or 
surgery to bone lesions, and new osteolytic bone lesions, 
were recorded until disease progression.
Statistical analysis
The sample size was calculated on the basis of the 
comparisons in chemotherapy regimens in the factorial 
design. In the intensive pathway, we aimed to recruit 
1080 patients (540 per group) to test the hypothesis that 
CTD was not inferior to CVAD, with a hazard ratio (HR) of 
1·2 and 80% power at a 5% signiﬁ cance level. In the non-
intensive pathway, we aimed to recruit 850 patients (425 per 
group) to assess whether CTDa was superior to standard 
chemotherapy with MP, with 80% power at a 5% 
signiﬁ cance level. We calculated that the sample size for 
the two pathways combined had suﬃ  cient power (>80%) 
to detect a reduction of 10% in the proportion of patients 
with skeletal-related events in patients on zoledronic acid 
compared with those on clodronic acid.
Analyses were based on the treatments that patients 
were randomised to receive and the intention-to-treat 
population, deﬁ ned as all randomised patients with 
histologically conﬁ rmed multiple myeloma who 
provided written informed consent. Between-group 
comparisons for overall survival and progression-free 
survival were done with Cox regression models stratiﬁ ed 
by pathway and adjusted for minimisation factors 
(including treatment centre) and type of induction 
chemotherapy. Between-group comparisons in overall 
response rate were assessed with logistic-regression 
models. We generated a Cox model for skeletal-related 
events, which included the minimisation factors, 
chemotherapy, and history of skeletal-related events at 
baseline (stratiﬁ ed by pathway); this model was used to 
calculate p values. A post-hoc analysis compared overall 
survival between patients randomised to receive 
zoledronic acid versus clodronic acid, with adjustment 
for time-dependent diﬀ erences in rates of skeletal-
related events.
Cox models were assessed for statistical violations. 
Adjustment for treatment centre in the Cox models of 
overall survival and progression-free survival was the 
only factor identiﬁ ed: a small treatment centre (n=12) 
reported unfavourable mortality results for patients 
treated with clodronic acid with a HR of 3·46 versus 
zoledronic acid. Additional exploratory analyses were 
done to validate the results when stratiﬁ cation by 
treatment centre was not included (based on the model 
violation), and to examine the relative eﬀ ects of zoledronic 
acid versus clodronic acid during the ﬁ rst few months on 
the study drug in response to rapid separation of the 
overall survival curves. Resultant exploratory analyses 
focused on the ﬁ rst 4 months and included Kaplan-Meier 
assessments of overall survival and progression-free 
survival and assessments of early deaths (within the ﬁ rst 
120 days on study drug) that were related to treatment or 
multiple myeloma.
The Kaplan-Meier analyses for overall survival were 
stratiﬁ ed by intensive versus non-intensive induction 
chemotherapy, with p values calculated by the log-rank 
test. HRs for overall and progression-free survival were 
developed with Cox proportional hazards models, 
stratiﬁ ed by pathway and adjusted for minimisation 
factors (treatment centre, haemoglobin, corrected 
serum calcium, serum creatinine, platelet count, and 
type of chemotherapy); p values were based on these 
models. For overall response rate, p values were 
calculated by logistic regression adjusted for 
minimisation factors (excluding treatment centre for 
exploratory post-hoc analyses because few patients were 
enrolled at some treatment centres) and chemotherapy. 
For between-group comparisons of adverse events, 
p values were calculated by Fisher’s exact test.
Statistical analyses were done with SAS (version 9.2) 
and Digital Visual Fortran software (version 6.0A). All 
tests were two-sided and at the 5% signiﬁ cance level, 
without adjustment for multiplicity.
This trial is registered, number ISRCTN68454111.
Role of the funding source
None of the funding organisations was involved in the 
study design, data collection, data analysis, data 
interpretation, writing of the report, or the decision to 
Zoledronic acid 
(n=981)
Clodronic acid 
(n=979)
Follow-up (years) 3·7 (2·8–4·7) 3·8 (2·9–4·7)
Still receiving bisphosphonate 111 (11%) 132 (13%)
Administration of bisphosphonate not conﬁ rmed 54 (6%) 36 (4%)
Discontinued study before disease progression 235 (24%) 185 (19%)
Disease progression or death 581 (59%) 626 (64%)
Time on treatment (days)
Intensive pathway 396 (152–737) 409 (152–727)
Non-intensive pathway 320 (138–520) 306 (111–505)
Data are median (IQR) or number (%).
Table 2: Treatment status
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submit for publication. All authors had full access to trial 
data, and the chief investigators had the ﬁ nal responsibility 
for the decision to submit for publication.
Results
Between May, 2003, and November, 2007, 1970 patients 
were recruited, of whom 1960 were eligible for analysis 
by intention to treat (ﬁ gure 1). Demographic and disease 
characteristics were well balanced between the zoledronic 
acid and clodronic acid groups at baseline (table 1). 
Patients in the intensive pathway were generally younger 
and had more aggressive bone disease than did those in 
the non-intensive pathway. Overall, most patients 
(about 97%, n=1898) were white, and 71% (n=1401) had 
myeloma bone disease.
By the cutoﬀ  date of Oct 5, 2009, most patients remained 
on treatment until disease progression or the end of the 
study period (n=746 for zoledronic acid, n=794 for clodronic 
acid). Median follow-up was 3·7 years (IQR 2·9–4·7), with 
patients receiving bisphosphonates for a median of 
350 days (IQR 137–632) before disease progression 
(table 2). Only 14 patients, ﬁ ve on zoledronic acid and nine 
on clodronic acid, had less than 12 months’ follow-up.
Our assumption that the intensity of induction 
chemotherapy would have no interaction with diﬀ erences 
in the endpoint of overall survival with zoledronic acid 
versus clodronic acid was valid (p=0·74 for the intensive 
pathway, p=0·13 for the non-intensive pathway), enabling 
the data to be analysed as a factorial trial, as per the 
Figure 2: Kaplan-Meier curves for patients randomised to zoledronic acid and clodronic acid for overall survival during the full follow-up period (A), overall 
survival during the ﬁ rst 4 months of treatment (B), progression-free survival during the full follow-up period (C), and progression-free survival during the 
ﬁ rst 4 months of treatment (D)
HR=hazard ratio.
Figure 3: Hazard ratios for overall survival and progression-free survival for zoledronic acid versus 
clodronic acid during the full follow-up period
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prespeciﬁ ed statistical plan. Proportional hazards were 
assessed by plotting HRs over time for each pathway and 
the model remained valid, with the possible exception of 
overall survival in the non-intensive pathway. In this 
pathway, although the hazards separated signiﬁ cantly 
from proportionality for type of induction chemotherapy 
(p=0∙011), the hazards did not separate signiﬁ cantly from 
proportionality (p=0∙30) during the ﬁ rst 4 months of 
treatment, wherein the main eﬀ ect on overall survival 
with zoledronic acid was recorded.
Overall survival signiﬁ cantly improved with zoledronic 
acid compared with clodronic acid during the full follow-
up period (ﬁ gure 2A) and during the ﬁ rst 4 months of 
treatment (ﬁ gure 2B). During the full follow-up period, 
zoledronic acid reduced mortality by 16% relative to 
clodronic acid (ﬁ gure 3). Other signiﬁ cant predictors of 
favourable overall survival were haemoglobin of 115 g/L 
or greater for men and of 95 g/L or greater for 
women (HR 0∙75, 95% CI 0∙65–0∙86; p<0∙0001), 
corrected serum calcium of less than 2·6 mmol/L (0∙69, 
0∙59–0∙80; p<0∙0001), serum creatinine of less than 
140 μmol/L (0∙75, 0∙64–0∙87; p=0∙0003), and platelet 
count of 150×10⁹/L or higher (0∙77, 0∙64–0∙93; 
p=0∙0056).
Although the study was not powered to detect a 
signiﬁ cant diﬀ erence between drug groups in the 
intensive and non-intensive pathways, overall survival 
was longer with zoledronic acid than with clodronic acid, 
although not signiﬁ cantly so, in both the 
intensive (HR 0·84, 95% CI 0·68–1·03; p=0·0854) and 
non-intensive pathways (0·83, 0·69–1·00; p=0·0492; 
table 3). Overall, zoledronic acid extended median overall 
survival by 5·5 months to 50·0 months (IQR 21·0 to not 
reached) compared with clodronic acid (44·5 months, 
IQR 16·5 to not reached; ﬁ gure 2A). During the ﬁ rst 
4 months of treatment, overall survival curves clearly 
separated between the drug groups (ﬁ gure 2B). When 
stratiﬁ cation by treatment centre was omitted, the beneﬁ t 
of zoledronic acid to overall survival remained signiﬁ cant 
compared with clodronic acid (HR 0·87, 95% CI 
0·77–0·99, p=0·037). For patients in the intensive and 
non-intensive pathways combined, more early deaths 
related to treatment regimen or multiple myeloma 
occurred with clodronic acid than with zoledronic acid 
(p=0·0008; table 4). During this time, signiﬁ cantly fewer 
patients on zoledronic acid had died of renal failure 
(p<0·0001), and fewer had died of infection, although the 
diﬀ erence was not signiﬁ cant (p=0·08), than did those 
on clodronic acid (table 4).
Zoledronic acid signiﬁ cantly improved progression-
free survival by 12% (ﬁ gure 3), and extended median 
progression-free survival by 2·0 months to 19·5 months 
(IQR 9·0–38·0) compared with clodronic acid 
(17·5 months, IQR 8·5–34·0). Although the diﬀ erence 
between drug groups was not signiﬁ cant for the full 
follow-up period (ﬁ gure 2C), early separation was recorded 
between the progression-free survival curves (ﬁ gure 2D). 
Intensive pathway Non-intensive pathway Overall
Zoledronic acid 
(n=555)
Clodronic acid 
(n=556)
Zoledronic acid 
(n=426)
Clodronic acid 
(n=423)
Zoledronic acid 
(n=981)
Clodronic acid 
(n=979)
Overall survival NR (61·0–NR) 62·5 (53·5–NR) 33·5 (29·5–36·5) 29·5 (25·5–34·0) 50·0 (46·0–60·5) 44·5 (42·0–51·5)
Progression-free survival 25·0 (23·5–28·5) 25·0 (22·5–27·0) 13·5 (12·0–14·0) 12·5 (11·5–13·5) 19·5 (18·0–21·0) 17·5 (16·5–19·5)
Data are median months (95% CI). NR=not reached.
Table 3: Overall and progression-free survival (intention-to-treat population)
Intensive pathway Non-intensive pathway Overall
Zoledronic acid 
(n=33)
Clodronic acid 
(n=44)
Zoledronic acid 
(n=32)
Clodronic acid 
(n=57)
Zoledronic acid 
(n=65)
Clodronic acid 
(n=101)
Related to multiple myeloma or treatment 27 37 20 47 47 84
Overwhelming cancer load 7 6 6 10 13 16
Infection 14 19 13 23 27 42
Renal failure 0 5 0 11 0 16
Other 6 7 1 3 7 10
Not related to multiple myeloma or treatment 6 7 12 10 18 17
Table 4: Primary causes of deaths within the ﬁ rst 120 days after randomisation
Intensive pathway Non-intensive pathway
Zoledronic acid 
(n=555)
Clodronic acid 
(n=556)
p value Zoledronic acid 
(n=426)
Clodronic acid 
(n=423)
p value
CR, VGPR, or PR 432 (78%) 422 (76%) 0·43 215 (50%) 195 (46%) 0·18
CR or VGPR* 200 (36%) 193 (35%) 0·63 85 (20%) 60 (14%) 0·018
CR* 78 (14%) 69 (12%) 0·42 39 (9%) 27 (6%) 0·13
CR=complete response. PR=partial response. VGPR=very good partial response. *Exploratory analyses.
Table 5: Response rates after induction therapy (intention-to-treat population)
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Progression-free survival was non-signiﬁ cantly extended 
with zoledronic acid as compared with clodronic acid in 
both the intensive (HR 0·90, 95% CI 0·78–1·05) and non-
intensive pathways (0·87, 0·74–1·01). We did not record 
any signiﬁ cant interactions between the four regimens of 
ﬁ rst-line bisphosphonate treatment plus induction chemo-
therapy and the diﬀ erences in overall and progression-free 
survival with zoledronic acid versus clodronic acid.
611 patients had a skeletal-related event before disease 
progression (27% [265/981] on zoledronic acid; 
35% [346/979] on clodronic acid; p=0·0004). In an 
exploratory analysis, we generated a Cox model including 
ﬁ rst skeletal-related event as a time-dependent covariate, 
which showed that improvement in overall survival with 
zoledronic acid versus clodronic acid remained signiﬁ cant 
(HR 0·85, 95% CI 0·74–0·97; p=0·018).
Overall response rates were higher with intensive than 
with non-intensive induction chemotherapy, irrespective 
of bisphosphonate treatment (table 5).19 For non-intensive 
therapy, zoledronic acid had a signiﬁ cantly increased rate 
of complete or very good partial response, and had a 
higher rate of complete response than did clodronic acid, 
although the diﬀ erence was not signiﬁ cant. For intensive 
therapy, rates of complete or very good partial response 
were not signiﬁ cantly diﬀ erent between drug groups.
The proﬁ le of adverse events was as expected for 
patients with multiple myeloma receiving bis-
phosphonate treatment plus induction chemotherapy 
(table 6). Occurrence of most adverse events was similar 
between the zoledronic acid and clodronic acid groups 
in both the intensive and non-intensive pathways. 
Overall, although more patients on zoledronic acid than 
on clodronic acid had serious adverse events, rates of 
treatment-emergent serious adverse events did not 
diﬀ er signiﬁ cantly between these drug groups. Of the 
treatment-emergent serious adverse events, signiﬁ cantly 
more patients on zoledronic acid developed bone and 
musculoskeletal disorders than did those on clodronic 
acid, and a lower rate of infections was recorded in the 
zoledronic acid group, but the diﬀ erence was not 
signiﬁ cant. Both ﬁ ndings might be related to immune-
system activation during an acute-phase reaction.
Rates of acute renal failure were low and similar for 
patients treated with zoledronic acid and clodronic acid 
in both the intensive and non-intensive pathways 
(table 6). Thromboembolic events were more common in 
the intensive pathway than in the non-intensive pathway, 
which was most probably caused by the administration 
of induction chemotherapy. Although thromboembolic 
events were more common in the overall population of 
patients on zoledronic acid than in those on clodronic 
acid, rates were not signiﬁ cantly diﬀ erent in each pathway 
separately. Conﬁ rmed osteonecrosis of the jaw was 
uncommon, but rates were higher for zoledronic acid 
than for clodronic acid (4% [35/983] vs <1% [3/979]; 
table 6). Recovery data for osteonecrosis of the jaw were 
available for nine patients on zoledronic acid and one on 
clodronic acid, and showed complete healing for three 
Intensive pathway Non-intensive pathway Overall 
p value*
Zoledronic acid 
(n=555)
Clodronic acid 
(n=556)
p value Zoledronic acid 
(n=428)†
Clodronic acid 
(n=423)
p value
Acute renal failure 29 (5%) 33 (6%) 0·70 28 (7%) 27 (6%) 1·0 0·78
Osteonecrosis of the jaw 21 (4%) 2 (<1%) <0·0001 14 (3%) 1 (<1%) 0·0009 <0·0001
Thromboembolic events 104 (19%) 82 (15%) 0·08 53 (12%) 35 (8%) 0·06 0·01
Any serious adverse event‡ 327 (59%) 280 (50%) 0·0046 212 (50%) 198 (47%) 0·45 <0·0001
No suspected association with study drugs 245 (44%) 214 (38%) 0·059 155 (36%) 161 (38%) 0·62 0·30
Any treatment-emergent serious adverse events§ 158 (28%) 141 (25%) 0·25 90 (21%) 85 (20%) 0·80 0·27
Blood and lymphatic system disorders 
(haematological disorders)
30 (5%) 26 (5%) 0·59 10 (2%) 8 (2%) 0·81 0·55
Cardiovascular disorders 40 (7%) 42 (8%) 0·91 33 (8%) 24 (6%) 0·27 0·60
Endocrine, metabolism, and nutrition disorders 6 (1%) 2 (<1%) 0·18 2 (<1%) 1 (<1%) 1·0 0·23
Gastrointestinal disorders 15 (3%) 12 (2%) 0·57 9 (2%) 18 (4%) 0·081 0·41
Infection 52 (9%) 62 (11%) 0·37 16 (4%) 28 (7%) 0·06 0·07
Musculoskeletal, connective tissue, and 
bone disorders
6 (1%) 2 (<1%) 0·18 11 (3%) 0 0·0009 0·0007
Nervous system disorders 10 (2%) 8 (1%) 0·64 8 (2%) 7 (2%) 1·0 0·73
Renal and urinary disorders 7 (1%) 8 (1%) 1·0 4 (1%) 6 (1%) 0·54 0·55
Skin and subcutaneous disorders 6 (1%) 3 (1%) 0·34 4 (1%) 6 (1%) 0·54 1·0
*p value for comparison of zoledronic acid (n=983) versus clodronic acid (n=979). †Two patients on zoledronic acid who were excluded from the non-intensive pathway 
because no consent was received were included in the safety population. ‡Irrespective of suspected association with study drugs; patients who had more than one type of 
adverse event have been listed against all relevant types of events, but patients who had more than one occurrence of the same type of event are recorded only once. 
§Suspected association with study drugs.
Table 6: Adverse events (safety population)
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patients on zoledronic acid, improvement for two patients 
on zoledronic acid, and no change for four patients on 
zoledronic acid and one patient on clodronic acid. Dental 
surgery or trauma was known to precede osteonecrosis 
of the jaw in six patients on zoledronic acid.
Discussion
Bisphosphonates are the standard of care for prevention of 
skeletal-related events and treatment of hypercalcaemia in 
patients with advanced cancer.1,3 In this large-scale, 
randomised trial of bisphosphonates in addition to 
standard induction chemotherapy for multiple myeloma, 
zoledronic acid was superior to clodronic acid across 
several endpoints. Zoledronic acid signiﬁ cantly improved 
overall survival and progression-free survival, with 
extension of overall survival by 5·5 months and 
progression-free survival by 2·0 months, and signiﬁ cantly 
reduced the proportion of patients with a skeletal-related 
event. Moreover, zoledronic acid improved overall survival 
independently of the reduction in skeletal-related events, 
suggesting that the drug has underlying antimyeloma 
eﬀ ects, which is consistent with higher (albeit not 
statistically signiﬁ cantly so) overall response rates in 
patients on zoledronic acid than in those on clodronic acid. 
Indeed, Child and colleagues established that response to 
induction chemotherapy for multiple myeloma signiﬁ cantly 
correlates with overall survival.20 Diﬀ erences in overall 
survival between the zoledronic acid and clodronic acid 
groups emerged within the ﬁ rst few months of treatment, 
supporting possible synergy of zoledronic acid with ﬁ rst-
line myeloma therapies or improved antimyeloma eﬀ ects 
of zoledronic acid when used early in the disease course.
Although improvements in disease outcomes with 
zoledronic acid are consistent with results from small 
controlled studies of zoledronic acid in newly diagnosed 
multiple myeloma (n=94) or early stage multiple 
myeloma (n=140),21,22 zoledronic acid had no signiﬁ -
cant beneﬁ ts to disease outcome in asymptomatic 
myeloma (n=163).23 This discrepancy is probably attrib-
utable to reduced risk of disease progression in 
asymptomatic disease and decreased statistical power 
with endpoints for disease outcomes. Indeed, most 
guidelines do not recommend bisphosphonates for 
smouldering myeloma because this disease has a fairly 
indolent nature.24,25 Additionally, most patients in our trial 
continued to receive bisphosphonate therapy until 
disease progression whereas, in other studies, the 
duration of bisphosphonate treatment with respect to 
disease course is uncertain.
Although existing practice at research institutes 
participating in our trial is to treat with bisphosphonates 
at least until disease progression, the optimal duration of 
bisphosphonate treatment needs further analysis. Society 
treatment guidelines are inconsistent with regard to the 
optimal duration of bisphosphonate therapy, especially 
in patients with overall disease remission.3,26 Indeed, in a 
study of maintenance therapy in patients who did not 
have disease progression within the ﬁ rst 2 months after 
autologous stem-cell transplantation (n=597), pamidronic 
acid did not improve event-free survival or overall survival 
versus no maintenance, whereas the combination of 
pamidronic acid and thalidomide improved both 
outcomes compared with no treatment or pamidronic 
acid alone.27 In our study, although the beneﬁ ts to overall 
survival of zoledronic acid versus clodronic acid were 
most pronounced early in the study, the overall survival 
curves separated throughout the study, suggesting 
potential for continuing beneﬁ t.
We used clodronic acid and zoledronic acid in our 
study because both are approved in the UK for 
prevention of skeletal-related events in multiple 
myeloma. Although zoledronic acid and clodronic acid 
are licensed for malignant bone lesions, not all patients 
had detectable bone disease at study entry. However, 
because bone lesions develop in virtually all patients 
during the disease course, bisphosphonate therapy was 
given to all patients. Although MRC Myeloma IX is not 
a placebo-controlled trial, the patterns of skeletal-related 
events were consistent with those in previous placebo-
controlled studies in multiple myeloma—eg, in 
Berenson and colleagues’ trial,9 44% of patients on 
placebo and 28% of those on pamidronic acid had a 
skeletal-related event within 1 year. Similarly, in the 
25-month randomised trial of pamidronic acid versus 
zoledronic acid,12,28 Rosen and colleagues reported 
skeletal-related events in 47% of patients on zoledronic 
acid versus 49% of those on pamidronic acid at 
13 months’ follow-up (a duration similar to the median 
time on study drug in our trial).
All intravenous bisphosphonates are associated with 
eﬀ ects on renal function that are dependent on dose and 
rate of infusion.29 Our study adhered strictly to the renal 
safety protocols speciﬁ ed in prescription information for 
zoledronic acid. The risk of renal failure was not 
signiﬁ cantly diﬀ erent between zoledronic acid and 
clodronic acid, despite use of thalidomide, a potentially 
nephrotoxic agent. This ﬁ nding is consistent with a 
report by Spencer and colleagues,30 in which renal safety 
proﬁ les did not diﬀ er signiﬁ cantly between zoledronic 
acid alone and zoledronic acid plus thalidomide in 
patients with multiple myeloma who were receiving 
maintenance therapy after autologous stem-cell 
transplantation. In our study, thromboembolic events 
were more common in the zoledronic acid group than in 
the clodronic acid group in both the intensive and non-
intensive pathways, but diﬀ erences were not signiﬁ cant. 
Further analyses of confounding variables (eg, indwelling-
catheter use) are needed to assess these diﬀ erences fully.
Our study provides important prospective data on 
occurrence of osteonecrosis of the jaw in patients with 
multiple myeloma, with adherence to best practice 
throughout the study. Although osteonecrosis of the jaw 
was more common in patients on zoledronic acid than in 
those on clodronic acid, the rates compare favourably 
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with those summarised in guidelines from the American 
Society of Clinical Oncology for bisphosphonate use in 
multiple myeloma,26 and most events were manageable 
and of low grade. According to reports in 2008–09, risk of 
osteonecrosis of the jaw can be further mitigated with 
dental hygiene programmes before start of bis-
phosphonates, and by use of prophylactic antibiotic 
therapy for oral surgery during bisphosphonate 
treatment.31–33 Implementation of such procedures might 
further reduce risk of osteonecrosis of the jaw in all 
patients, and might have prevented some of the events 
recorded in our trial.
As with most large trials, the MRC Myeloma IX trial 
does not provide deﬁ nitive answers to all the questions it 
sought to address. The regimens and practices common 
at the start of the study have since developed. Nonetheless, 
the study drugs were integrated into the latest 
chemotherapy regimens, which remain cornerstones of 
antimyeloma therapy. Because the trial was designed to 
compare several treatment options, some statistically 
signiﬁ cant eﬀ ects could have been chance ﬁ ndings. 
However, we believe that our ﬁ ndings are robust because 
signiﬁ cant diﬀ erences in the main ﬁ ndings had low 
p values, and we used in-depth and comprehensive 
statistical models and analyses, such as exploratory 
analyses showing a signiﬁ cant beneﬁ t to overall survival 
with zoledronic acid during the ﬁ rst 4 months. Another 
limitation of any study of oral therapies is the potential 
for poor compliance. We are not able to distinguish the 
eﬀ ects of poor compliance in our study from the 
inherently lower eﬃ  cacy of the oral bisphosphonate 
clodronic acid versus zoledronic acid. However, clinically 
the end result is the same, supporting preferential use of 
zoledronic acid. The intravenous bisphosphonate 
pamidronic acid, a bisphosphonate with antiresorptive 
activity intermediate between clodronic acid and 
zoledronic acid,4 is also approved for prevention of 
skeletal-related events in this setting. Therefore, the MRC 
Myeloma IX trial leaves several questions unanswered, 
including whether pamidronic acid might also oﬀ er 
beneﬁ ts to progression-free survival and overall survival 
versus clodronic acid.
Adverse events in our trial were consistent with the 
established tolerability proﬁ les of zoledronic acid and 
clodronic acid in multiple myeloma. One exception was 
that renal adverse events occurred at a similar rate for 
both bisphosphonates, despite the fact that one drug was 
given orally and the other intravenously, suggesting that 
the aetiology of these events could stem from the 
underlying disease. Indeed, fewer early deaths from renal 
failure occurred in the zoledronic acid group than in the 
clodronic acid group.
The improvement in overall survival with zoledronic 
acid remained signiﬁ cant after adjustment for the 
reduction in risk of skeletal-related events. These data 
add to growing clinical evidence supporting anticancer 
beneﬁ ts with zoledronic acid in patients with newly 
diagnosed cancers.14,21 According to preclinical studies of 
zoledronic acid, this improvement could occur via several 
potential mechanisms of action, including proapoptotic 
eﬀ ects on cancer cells, cytotoxic synergy with chemo-
therapeutic agents, antiangiogenesis, interference with 
adhesion of cancer cells, and stimulation of host 
anticancer immune responses.4,7,8 The improvements in 
complete or very good partial response in our trial 
support synergy between zoledronic acid and induction 
therapy. Although we have not deﬁ nitively identiﬁ ed the 
underlying mechanism of action, the early improvement 
in overall survival with zoledronic acid compared with 
clodronic acid supports early use of zoledronic acid in 
multiple myeloma.
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